FDA approves Novo Nordisk's Awiqli®, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
PR Newswire —
Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA1 Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per week1 The Awiqli® approval reflects Novo...